A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors. Issue 6 (June 2018)

• Record Type: Journal Article
• Authors: Pusceddu, Sara; Barretta, Francesco; Trama, Annalisa; Botta, Laura; Milione, Massimo; Buzzoni, Roberto; De Braud, Filippo; Mazzaferro, Vincenzo; Pastorino, Ugo; Seregni, Ettore; Mariani, Luigi; Gatta, Gemma; Di Bartolomeo, Maria; Femia, Daniela; Prinzi, Natalie; Coppa, Jorgelina; Panzuto, Francesco; Antonuzzo, Lorenzo; Bajetta, Emilio; Brizzi, Maria Pia; Campana, Davide; Catena, Laura; Comber, Harry; Dwane, Fiona; Fazio, Nicola; Faggiano, Antongiulio; Giuffrida, Dario; Henau, Kris; Ibrahim, Toni; Marconcini, Riccardo; Massironi, Sara; Žakelj, Maja Primic; Spada, Francesca; Tafuto, Salvatore; Van Eycken, Elizabeth; Van der Zwan, Jan Maaten; Žagar, Tina; Giacomelli, Luca; Miceli, Rosalba;
• Other Names: author non-byline.; Aroldi Francesca author non-byline.; Bongiovanni Alberto author non-byline.; Berardi Rossana author non-byline.; Brighi Nicole author non-byline.; Cingarlini Sara author non-byline.; Cauchi Carolina author non-byline.; Cavalcoli Federica author non-byline.; Carnaghi Carlo author non-byline.; Corti Francesca author non-byline.; Duro Marilina author non-byline.; Davì Maria Vittoria author non-byline.; De Divitiis Chiara author non-byline.; Ermacora Paola author non-byline.; La Salvia Anna author non-byline.; Luppi Gabriele author non-byline.; Lo Russo Giuseppe author non-byline.; Nichetti Federico author non-byline.; Raimondi Alessandra author non-byline.; Perfetti Vittorio author non-byline.; Razzore Paola author non-byline.; Rinzivillo Maria author non-byline.; Siesling Sabine author non-byline.; Torchio Martina author non-byline.; Van Dijk Boukje author non-byline.; Visser Otto author non-byline.; Vernieri Claudio author non-byline.
• Is Part Of: Endocrine-related cancer. Volume 25:Issue 6(2018)
• Page Start: 607
• Page End: 618
• Publication Date: 2018-06
• Subjects: neuroendocrine tumors -- overall survival -- prognosis -- prognostic score -- validation; Endocrine glands -- Cancer -- Periodicals; Endocrinology -- Periodicals; Cancer -- Endocrine aspects -- Periodicals; 616.9944005
• DOI: 10.1530/ERC-17-0489
• Languages: English
• ISSNs: 1351-0088

Abstract

Abstract : No validated prognostic tool is available for predicting overall survival (OS) of patients with well-differentiated neuroendocrine tumors (WDNETs). This study, conducted in three independent cohorts of patients from five different European countries, aimed to develop and validate a classification prognostic score for OS in patients with stage IV WDNETs. We retrospectively collected data on 1387 patients: (i) patients treated at the Istituto Nazionale Tumori (Milan, Italy; n = 515); (ii) European cohort of rare NET patients included in the European RARECAREnet database ( n = 457); (iii) Italian multicentric cohort of pancreatic NET (pNETs) patients treated at 24 Italian institutions ( n = 415). The score was developed using data from patients included in cohort (i) (training set); external validation was performed by applying the score to the data of the two independent cohorts (ii) and (iii) evaluating both calibration and discriminative ability (Harrell C statistic). We used data on age, primary tumor site, metastasis (synchronous vs metachronous), Ki-67, functional status and primary surgery to build the score, which was developed for classifying patients into three groups with differential 10-year OS: (I) favorable risk group: 10-year OS ≥70%; (II) intermediate risk group: 30% ≤ 10-year OS < 70%; (III) poor risk group: 10-year OS <30%. The Harrell C statistic was 0.661 in the training set, and 0.626 and 0.601 in the RARECAREnet and Italian multicentric validation sets, respectively. In conclusion, based on the analysis of three 'field-practice' cohorts collected in different settings, we defined and validated a prognostic score to classify patients into three groups with different long-term prognoses.